0001437749-23-002264.txt : 20230201 0001437749-23-002264.hdr.sgml : 20230201 20230201163717 ACCESSION NUMBER: 0001437749-23-002264 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230130 FILED AS OF DATE: 20230201 DATE AS OF CHANGE: 20230201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Simpson Jennifer K. CENTRAL INDEX KEY: 0001545253 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39468 FILM NUMBER: 23577317 MAIL ADDRESS: STREET 1: C/O DELCATH SYSTEMS, INC. STREET 2: 810 SEVENTH AVENUE, SUITE 3505 CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Panbela Therapeutics, Inc. CENTRAL INDEX KEY: 0001029125 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870543922 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 712 VISTA BLVD #305 CITY: WACONIA STATE: MN ZIP: 55387 BUSINESS PHONE: 9524791196 MAIL ADDRESS: STREET 1: 712 VISTA BLVD #305 CITY: WACONIA STATE: MN ZIP: 55387 FORMER COMPANY: FORMER CONFORMED NAME: Sun BioPharma, Inc. DATE OF NAME CHANGE: 20150911 FORMER COMPANY: FORMER CONFORMED NAME: Cimarron Medical, Inc. DATE OF NAME CHANGE: 20150602 FORMER COMPANY: FORMER CONFORMED NAME: CIMARRON SOFTWARE INC DATE OF NAME CHANGE: 19961217 4 1 rdgdoc.xml FORM 4 X0306 4 2023-01-30 0001029125 Panbela Therapeutics, Inc. PBLA 0001545253 Simpson Jennifer K. 712 VISTA BLVD #305 WACONIA MN 55387 1 1 President and CEO Common Stock 2023-01-30 4 P 0 4444 A 7868 D Warrants (right to buy) 2.75 2023-01-30 4 P 0 8888 0 A 2023-01-30 2028-01-30 Common Stock 8888 8888 D Reported securities purchased as one share of common stock and one warrant to purchase two shares of common stock for a combined price of $2.25 per share and warrant. On or after March 1, 2023, holder may elect an "alternative cashless exercise" pursuant to which they would receive an aggregate number of shares of common stock equal to 75% of the aggregate number of shares that would be issuable upon a cash exercise. /s/ Joshua L. Colburn, Attorney-in-Fact 2023-02-01